- Home
- LRN vs KNSA Comparison
LRN vs KNSA Comparison
Compare LRN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRN | KNSA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LRN | KNSA |
|---|---|---|
| Price | $94.80 | $52.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $106.75 | $58.43 |
| AVG Volume (30 Days) | 599.9K | ★ 742.4K |
| Earning Date | 04-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.87 | ★ 225.00 |
| EPS | ★ 5.39 | 0.27 |
| Revenue | ★ $917,734,000.00 | $677,564,000.00 |
| Revenue This Year | $6.18 | $37.48 |
| Revenue Next Year | $4.74 | $17.87 |
| P/E Ratio | ★ $26.63 | $71.19 |
| Revenue Growth | 3.29 | ★ 60.09 |
| 52 Week Low | $60.61 | $25.71 |
| 52 Week High | $171.17 | $54.23 |
Technical Indicators
Market Signals| Indicator | LRN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.91 | 66.79 |
| Support Level | $81.27 | $40.67 |
| Resistance Level | $150.26 | N/A |
| Average True Range (ATR) | 3.82 | 2.20 |
| MACD | -0.39 | 0.68 |
| Stochastic Oscillator | 47.18 | 85.60 |
Price Performance
Historical ComparisonAbout LRN Stride Inc.
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.